Clinical trial
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in…
NCT00033371 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00033371 |
|---|---|
| Title | Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis |
| Official title | A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Familial Adenomatous Polyposis |
| Intervention type | Drug, Other |
| Interventions | Celecoxib, Placebo, eflornithine, Laboratory biomarker analysis, Questionnaire administration |
| Enrollment | 205 |
| Start date | Dec 13, 2001 |
| Primary completion | Feb 24, 2009 |
| Completion | Mar 24, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 29, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: